Lung Cancer

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Brigatinib reduced the risk of disease progression or death by more than 50% compared to crizotinib in adult patients with ALK-positive, locally advanced or metastatic NSCLC.

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.

The addition of atezolizumab to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival in patients with stage IV nonsquamous NSCLC.

Wade T. Iams, MD, and Erin A. Gillaspie, MD, MPH, discuss the impact that immunotherapy has had on the treatment of patients with early-stage non–small cell lung cancer.

Repotrectinib (TPX-0005) demonstrates a clinically meaningful and durable benefit across multiple doses in patients with ROS1 fusion–positive NSCLC.

Poziotinib demonstrated high antitumor activity in patients with metastatic, heavily pretreated EGFR and HER2 exon 20 mutant non–small cell lung cancer.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the potential impact of implementing cell-free DNA tests as a method to detect signs of early stage cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended full approval of brigatinib (Alunbrig) as a treatment for patients with advanced ALK-positive non–small cell lung cancer who are previously treated with crizotinib (Xalkori).

Heather Wakelee, MD, shares insight on emerging treatment strategies in EGFR–positive non–small cell lung cancer.

Patrick M. Forde, MBBCh, discusses the advances in early-stage non–small cell lung cancer, emphasizing neoadjuvant and adjuvant immunotherapy trials in stage I, II, and III disease.

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the treatment of patients with early-stage non–small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses immunotherapy for patients with stage IV non–small cell lung cancer.

Josephine L. Feliciano, MD, discusses established and emerging therapeutic developments for patients with non–small cell lung cancer with less common driver mutations.

The FDA has granted a priority review designation to single-agent pembrolizumab for the frontline treatment of patients with locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer with PD-L1 expression ≥1% and no EGFR or ALK genomic tumor aberrations.

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses impactful targeted therapies in lung cancer.

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Josephine L. Feliciano, MD, discusses the role of immunotherapy and the potential of targeted agents in small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer or RET-mutant medullary thyroid cancer.